Therapeutic Area
Metabolic Disease CDMOs
Compare CDMOs with metabolic disease manufacturing expertise for GLP-1 agonists, insulin analogs, and oral antidiabetics. Filter by peptide capabilities, dosage form, and scale.
101 companies listed
About Metabolic Disease Drug Manufacturing
The metabolic disease space is experiencing unprecedented demand growth, driven by GLP-1 receptor agonists (semaglutide, tirzepatide) for diabetes and obesity. Global GLP-1 manufacturing capacity is severely constrained, with demand outstripping supply by an estimated 2-3x. CDMOs with peptide synthesis, fermentation-based peptide production, and prefilled pen/syringe fill-finish capabilities are the most sought-after partners in pharma.
Peptide manufacturing is the bottleneck. GLP-1 agonists are peptides produced either by solid-phase peptide synthesis (SPPS) or recombinant DNA technology. SPPS is suitable for shorter peptides but faces scale limitations. Recombinant production in E. coli or yeast (Pichia pastoris) enables larger scale but requires fermentation expertise, refolding optimization, and complex purification. CDMOs that can offer both approaches provide sponsors with optionality.
Device integration drives complexity. Most metabolic disease injectables are delivered via pen injectors or autoinjectors for patient self-administration. CDMOs need cartridge filling capability (3mL cartridges for pens), device assembly experience, and combination product regulatory knowledge. The fill-finish step for cartridges requires different equipment and expertise than standard vial filling.
Companies (101)
Thermo Fisher Scientific Inc.
China
One of the world's largest pharmaceutical CDMOs through its Patheon pharma services division. Provides end-to-end pharmaceutical development and manufacturing services for both small molecules and biologics, from API manufacturing through drug product, sterile fill/finish, packaging, and commercial supply. Operates 31+ FDA-registered facilities globally. 158 FDA inspections on record (52 NAI, 104 VAI, 2 OAI). Also provides cell therapy manufacturing solutions (CTS Rotea cell processing system), laboratory informatics, bioprocessing equipment, and reagents. 4 FDA-approved drug products. Revenue >$40B (full company).
Small Molecule APISmall Molecule Drug ProductOral Solid Dose
Tiefenbacher Group
Cyprus
Purpose-driven, family-owned healthcare company pioneering healthcare since 1963, headquartered in Cyprus. Delivers best-in-class solutions across the entire pharmaceutical value chain from API distribution through development, manufacturing, and registration of affordable medicines. 900+ employees, 400+ customers, 180+ finished dosage form products, serving patients in 80+ countries. Production capacity up to 3 billion units per year. Manufacturing sites in Cyprus (large-scale oral solid dose, SPC waiver site) and Hyderabad, India (specialized high-potent manufacturing block for oncology, FDA-inspected). Includes Tiefenbacher Laboratories (TBD Pharmatech) as API CDMO division. Offers ICH stability studies, technology transfer, analytical laboratory services, and EU batch testing/release.
Frequently Asked Questions
Why is GLP-1 manufacturing capacity so constrained?+
Three factors converge. First, the clinical success of semaglutide and tirzepatide expanded the addressable market from 500 million diabetes patients to over 1 billion when obesity is included. Second, peptide manufacturing (whether synthetic or recombinant) is inherently lower throughput than small molecule or antibody manufacturing. Third, building new peptide manufacturing capacity takes 3-5 years from ground-breaking to GMP production. The gap between demand and supply will persist through at least 2027-2028.
What capabilities should a metabolic disease CDMO have?+
Need help finding the right CDMO?
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.
